What changed in Neurocrine Biosciences Inc's latest annual report
In the year ended 31 Dec 2025, Neurocrine Biosciences Inc's revenue rose 21.4% to USD 2.86bn, from USD 2.36bn; net income rose 40.2% to USD 478.60m, from USD 341.30m; cash and cash equivalents rose 206% to USD 713.00m, from USD 233.00m.
Year ended 31 Dec 2025. Source: 10-K filed 11 Feb 2026, read it on SEC EDGAR.
USD 2.36bn to USD 2.86bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 2.36bn | 2.86bn | Up 21.4% |
| Net income | 341.30m | 478.60m | Up 40.2% |
| Total assets | 3.72bn | 4.63bn | Up 24.5% |
| Total liabilities | 1.13bn | 1.38bn | Up 22.1% |
| Cash and cash equivalents | 233.00m | 713.00m | Up 206% |
| Shareholders' equity | 2.59bn | 3.25bn | Up 25.6% |
Questions people ask
Did Neurocrine Biosciences Inc's revenue grow last year?
Revenue grew 21.4%, from USD 2.36bn to USD 2.86bn in the year ended 31 Dec 2025.
Is Neurocrine Biosciences Inc profitable?
Yes. Net income was USD 478.60m in the year ended 31 Dec 2025. The year before: USD 341.30m.
How much cash and debt does Neurocrine Biosciences Inc have?
At its latest year end (31 Dec 2025), Neurocrine Biosciences Inc reported cash and cash equivalents of USD 713.00m.
Where do these numbers come from?
From Neurocrine Biosciences Inc's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Neurocrine Biosciences Inc?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Gilead Sciences, Inc.Net income up 1672.9%
- Moderna, Inc.Revenue down 39.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Biogen Inc.Net income down 20.8%
- Exelixis IncCash and cash equivalents up 122%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%
- Repligen CorpCash and cash equivalents down 25.3%